Smoking Cessation: A Cardiologist's Patient Guide to Quitting for Your Heart

I’ve watched a lot of patients try to quit smoking. A few succeeded on the first attempt. Most didn’t. What that experience and the outcomes literature both say is the same thing: quitting is the single highest-impact intervention available to anyone with a heart. No statin, no blood pressure medication, no bypass operation delivers the same size of risk reduction.

This isn’t a lecture. Most smokers want to quit, and they aren’t weak or undisciplined. Nicotine has dependence potential comparable to heroin or cocaine, and quitting is hard because years of exposure have chemically rewired the brain. The medications have improved a great deal over the past 15 years, and most people who keep trying eventually succeed.

What Smoking Does to Your Heart

Cigarette smoke contains about 7,000 chemicals, dozens with direct cardiovascular toxicity. Three do most of the damage. Nicotine activates the sympathetic nervous system, raising heart rate and blood pressure with every puff and, over years, pushing resting blood pressure up. Carbon monoxide binds hemoglobin, the oxygen-carrying protein in red blood cells, more than 200 times more tightly than oxygen does, so a smoker’s blood carries less oxygen and the heart muscle runs chronically oxygen-poor. Oxidizing particulates damage the endothelium, the thin lining of blood vessels that controls vascular tone, inflammation, and clotting, and endothelial damage is the first step toward atherosclerosis.

The result is plaque that builds earlier and faster. A 30-year-old smoker has a vascular age closer to 40, and by their 50s many smokers carry coronary disease that otherwise wouldn’t appear until their 70s. Smoking also raises platelet reactivity and fibrinogen, so clots form more readily on damaged vessel walls, which is why smokers have more heart attacks, strokes, and peripheral artery disease.

In numbers: heart attack risk is nearly 3 times that of never-smokers and higher still in younger smokers. Ischemic stroke risk roughly doubles, and smoking contributes to hemorrhagic stroke too. Sudden cardiac death risk rises about 2.5-fold. Abdominal aortic aneurysm risk rises about fivefold, making smoking the single most modifiable risk factor for that condition. Peripheral artery disease rates climb substantially, which can progress to chronic leg pain, non-healing wounds, and amputation. Smoking contributes to heart failure and modestly raises atrial fibrillation risk and worsens control of established AFib. Overall, smoking causes about 1 in 4 cardiovascular deaths globally.

There’s no safe level. Even 1 cigarette per day carries roughly half the coronary heart disease risk of a 20-cigarette-per-day habit.

What Happens When You Quit

Recovery starts fast. Within 20 minutes heart rate and blood pressure begin falling toward your baseline. Within 8 hours carbon monoxide levels drop substantially, and by 12 hours they approach normal and oxygen delivery improves. Within 24 hours heart attack risk has already begun to decline.

Over 2 to 3 weeks circulation improves measurably and walking gets easier, though your cough may temporarily worsen as the cilia in your airways regenerate and clear accumulated mucus. From 1 to 9 months, cough and shortness of breath improve substantially. At 1 year, coronary heart disease risk has dropped by about half compared to someone who kept smoking. By 5 years, stroke risk approaches the never-smoker level for most quitters, and within 5 to 15 years it gets there for nearly everyone. At 10 to 15 years coronary heart disease risk approaches never-smoker levels for light smokers, while heavy smokers with more than 20 pack-years may need 20 to 25 years. The benefit keeps accumulating. There’s no point at which quitting stops paying.

If you already have coronary disease the payoff is bigger. The 2022 Cochrane review of cessation after cardiovascular events found a 39 percent reduction in cardiovascular mortality (hazard ratio 0.61) and a 43 percent reduction in major adverse cardiovascular events (hazard ratio 0.57) in quitters versus continuing smokers. That’s a larger mortality benefit than any medication we prescribe after a heart attack, aspirin and statins and beta-blockers included. It’s why stopping smoking is the thing I push hardest on every post-heart-attack patient.

Age changes the size of the benefit but never eliminates it. Quitting before 40 removes roughly 90 percent of the excess death risk from smoking. Quitting at 45 adds roughly 6 years of life expectancy, at 55 roughly 4 years, and at 65 about 2 years. Even after 65 you buy meaningful time, and the breathing, energy, and cough improvements start immediately.

Why Quitting Is So Hard

Nicotine binds nicotinic acetylcholine receptors in the brain and triggers dopamine release in the reward center, the same pathway other addictive drugs use. The brain adapts fast. Receptor density changes, sensitivity shifts, and eventually the brain needs nicotine to feel normal.

Withdrawal starts within hours of the last cigarette: irritability and short temper, anxiety, trouble concentrating, restlessness, increased appetite, sometimes low mood, and intense craving. Symptoms peak in the first 3 to 5 days and improve over 2 to 4 weeks, though occasional cravings and appetite changes can last months. Withdrawal isn’t dangerous, but it’s deeply uncomfortable, and that discomfort drives most first-week relapses.

Then there’s the behavioral layer. Smoking is welded to routine, to morning coffee, to the moment after a meal, to stress, to particular friends and places. Those cues keep triggering craving long after the nicotine has cleared. Walking past your old smoke break spot 6 months into a quit can still hit hard.

Which is why willpower alone usually loses. The relapse rate for unassisted attempts is about 95 percent, meaning a success rate near 5 percent. Add medication and behavioral support and one-year success rates triple or quadruple. Using medication doesn’t mean you lack willpower. It means you’ve made a hard task more achievable.

The Medications That Work

Three categories are FDA-approved. The 2023 Cochrane network meta-analysis, covering 319 randomized trials and more than 157,000 participants, found that varenicline and combination nicotine replacement therapy roughly double placebo quit rates, while single-form NRT and bupropion raise quit rates by about 40 percent. Current AHA/ACC guidelines list varenicline or combination NRT as first-line for smokers with stable cardiovascular disease.

Nicotine replacement delivers nicotine without the 7,000 combustion byproducts. The patch gives steady background coverage to blunt withdrawal, and short-acting forms (gum, lozenge, inhaler, nasal spray) handle breakthrough cravings. Combination therapy, a patch plus a short-acting rescue form, is the most effective NRT strategy and performs comparably to varenicline, well ahead of the patch alone. Patch dosing usually starts at 21 mg per day for heavy smokers at more than 10 cigarettes daily, 14 mg for moderate smokers, and 7 mg for light smokers, tapering over 8 to 12 weeks. NRT is safe in stable cardiovascular disease, including after a heart attack. The risk of continuing to smoke vastly exceeds any risk from NRT.

Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic receptor, giving enough stimulation to reduce withdrawal while blocking full activation if you do smoke, which blunts the pleasure of a relapse cigarette. The EAGLES trial found biochemically confirmed continuous abstinence at weeks 9 through 24 of 21.8 percent on varenicline, against 16.2 percent for bupropion, 15.7 percent for the nicotine patch, and 9.4 percent for placebo. EAGLES also showed no excess neuropsychiatric adverse events versus placebo, and the FDA removed varenicline’s black box warning for psychiatric events in 2016 on the strength of it. The EVITA trial, in patients hospitalized with acute coronary syndrome, raised 52-week point-prevalence abstinence from 29 percent to 40 percent with no excess in major cardiovascular events. Standard dosing is 0.5 mg once daily for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily from day 8 through week 12, sometimes extended to 24 weeks in patients doing well. Nausea is the most common side effect and usually settles after the first few weeks; taking it with food helps. Vivid dreams are common and usually tolerable.

Bupropion is an atypical antidepressant that also reduces craving and withdrawal. It’s less effective than varenicline or combination NRT, but it’s a reasonable choice alongside depression, when NRT isn’t tolerated, or when you’d rather take a pill. Avoid it with a seizure disorder, an active eating disorder, or recent alcohol or sedative withdrawal, since it lowers the seizure threshold. Dosing is 150 mg once daily for 3 days, then 150 mg twice daily, started 1 to 2 weeks before the quit date and continued 7 to 12 weeks.

Combining varenicline with NRT, or bupropion with NRT, is increasingly used in strong dependence or after failed attempts. The combinations are generally safe and may improve quit rates further.

Medication alone works; medication plus counseling works better. Even a 5-minute discussion at a visit improves quit rates. Quitline counseling is free in every US state, and text-message programs and apps like Smokefree.gov have randomized evidence behind them. The National Cancer Institute quitline at 1-800-QUIT-NOW is the easiest entry point, free, anonymous, and available in multiple languages.

What About E-Cigarettes?

The short-term efficacy data are real. Randomized trials and the 2025 Cochrane living systematic review show e-cigarettes increase quit rates by about 55 percent compared to NRT (relative risk 1.55), and the Hajek 2019 NEJM trial reported 18 percent one-year abstinence on e-cigarettes versus 9.9 percent on NRT.

The concerns are also real. They appear more effective than NRT for short-term cessation in some studies, but they aren’t FDA-approved for smoking cessation, and long-term cardiovascular safety data are limited. We have decades of data on cigarettes and only a few years on vaping. Vaping carries its own cardiovascular risks including elevated blood pressure, endothelial dysfunction, platelet activation, and in some observational studies more chest pain and arrhythmias. And the most worrying pattern is dual use, since pooled data show dual users carry roughly 36 percent higher cardiovascular disease risk than exclusive combustible smokers (odds ratio 1.36). Adding vaping to smoking makes things worse.

So my approach is to try the FDA-approved therapies first. If those fail repeatedly and you’re motivated to switch completely to e-cigarettes as a harm-reduction bridge, we discuss the tradeoffs honestly and set a timeline for tapering off the vape too. I never recommend starting e-cigarettes for someone who isn’t already smoking, and for teens and young adults who don’t smoke the message is simply don’t start.

What About the Weight Gain?

About 80 percent of quitters gain some weight, typically 7 to 13 pounds in the first year, and about 13 percent gain more than 22 pounds. Nicotine suppresses appetite and raises metabolic rate, and both effects reverse when you stop. The gain levels off; most quitters don’t keep gaining after year one.

Here’s the part patients rarely expect. The 2018 NEJM analysis by Hu and colleagues, drawing on three large US cohorts, found that compared to continuing smokers, quitters who gained 5 to 10 kilograms had a 75 percent lower risk of cardiovascular death (hazard ratio 0.25), while quitters who gained no weight had a 31 percent lower risk (hazard ratio 0.69). Post-cessation weight gain doesn’t erase the benefit of quitting. It travels with a larger survival benefit, not a smaller one.

If the weight still worries you, a few things help. Stock healthier snacks for the first few weeks, keep a regular eating schedule, and pre-portion instead of eating from open packages. Walk 30 minutes a day, which reduces post-quit gain and lifts mood, which helps the quit itself. Protect your sleep at 7 to 9 hours, since withdrawal disrupts it and poor sleep drives more eating. Limit alcohol, which is both a calorie source and a common relapse trigger. And GLP-1 receptor agonists are worth discussing. In a 2023 randomized trial, dulaglutide produced about 3 kilograms less weight gain than placebo when added to varenicline and counseling. GLP-1 agonists don’t appear to improve abstinence rates themselves, but they address one of the most common reasons patients give for avoiding cessation, and they carry independent cardiovascular benefit. See our guide to GLP-1 cardioprotection for more.

Building Your Quit Plan

Pick a specific quit date within the next 2 weeks, ideally with a low-stress day or two at the start. Don’t schedule it the night before a big presentation or a family wedding, and don’t postpone 6 months waiting for a perfect window that never arrives.

Get the medication in hand and started before that date. Varenicline starts 7 days ahead so you’re at full dose by quit day. Bupropion starts 1 to 2 weeks ahead. The NRT patch usually starts on quit day, with short-acting forms on hand from day one. Fill the prescription early and put the medication on your nightstand.

Clear the environment. Cigarettes, lighters, and ashtrays out of the home, car, and office, with no “just one pack in case,” because hidden cigarettes find you in a moment of stress. Wash the clothing and clean the spaces that smell of smoke, since the smell alone triggers cravings. If you live with a smoker, talk about whether they’ll quit with you or at least keep it out of the house and car.

Tell family and friends the date and tell them how to help, which usually means not asking constantly how the quit is going. Call 1-800-QUIT-NOW. Consider a text program like SmokefreeTXT, and in-person group or individual counseling if that suits you.

Then make a trigger list, morning coffee, after meals, driving, stress at work, social drinking, particular people and places, and plan a substitute for each. Switch to tea for a week or drink coffee somewhere else. Get up immediately after meals, take a 5-minute walk, brush your teeth. Clean the car and take a different route. Keep a list of non-smoking stress responses ready, deep breathing, a 10-minute walk, calling a friend, cold water. Stay in non-smoking environments for the first 2 to 4 weeks where you can, and limit alcohol, which is the single most common relapse trigger. Protect the end of the day too. Go to bed at a consistent time. Avoid screens for 30 to 60 minutes before bed (sleep disturbance is common in withdrawal).

Most cravings last 3 to 5 minutes and pass on their own. The 4 D’s carry a lot of people through: delay by telling yourself five more minutes, distract by doing something with your hands or changing rooms, drink water, and deep breathe. Use your short-acting NRT for breakthrough cravings, call your support person, walk, or brush your teeth.

Getting Through the First Weeks

Days 1 through 7 are the worst. Withdrawal peaks, cravings come hard and often, and you may feel irritable, scattered, and tired, with disturbed sleep, headaches, or dizziness. Stick to the plan, use short-acting NRT, walk, drink water, avoid high-risk situations, and postpone difficult conversations and major decisions if you can.

Through weeks 2 to 4 the physical symptoms fade and sleep and energy return, though triggered cravings can still be intense. Keep taking the medication, build routines around exercise and regular meals and sleep, and watch for the relief relapse, the single cigarette taken to defuse stress that usually turns into a full relapse.

By months 2 and 3 most physical withdrawal is gone and lung function is noticeably better. Stay on the medication for the full prescribed course, typically 12 weeks, and don’t taper early. Watch for the “I’ve got this” overconfidence that so often comes right before a relapse. Through months 4 to 12, most quitters feel normal, with infrequent cravings that can still land hard during stress or social pressure. Complete the medication course and keep the support going. One cigarette can restart the whole cycle. That stays true past the first year.

Set up follow-up rather than leaving it to chance. See your primary care doctor or cardiologist at 1 to 2 weeks to check how you’re tolerating the medication and troubleshoot side effects, then again at 1 month, 3 months, and 6 months. Continued follow-up substantially improves long-term success. If you’ve quit before and relapsed, the next attempt should use a different combination, a longer duration, or more behavioral support rather than a repeat of what didn’t hold.

Slips happen, and one cigarette doesn’t have to mean full relapse. Don’t catastrophize. Identify what triggered it, adjust the plan for that trigger, get straight back on the medication, and call your support person or the quitline. Repeated slipping is a signal to change the medication plan, not to give up.

Common Questions

How many attempts does this usually take?

The average successful quitter makes between 7 and 30 attempts. Each one teaches you something about what triggers relapse and what helps. A previous failure isn’t a prediction, it’s information for the next attempt.

Should I quit before surgery?

Yes. Even a few weeks of cessation before an operation improves wound healing, reduces respiratory complications, and improves cardiovascular outcomes. A hospitalization is a good launching point, with NRT in the hospital and structured follow-up afterward.

What if I’m pregnant?

Stop as soon as you can. NRT can be used in pregnancy if behavioral approaches haven’t worked, though typically at lower doses and shorter duration. Varenicline and bupropion are generally avoided. Discuss it with your obstetric team.

What about nicotine pouches like Zyn, or chewing tobacco?

Neither involves combustion, and neither is FDA-approved for cessation. Cardiovascular risk is lower than cigarettes but still real, and long-term data on pouches are limited. They may work as a harm-reduction step, but the goal should be getting off nicotine entirely, using NRT or varenicline for the transition.

Will insurance cover the medications?

Most US plans, including Medicare and Medicaid, cover cessation medications and counseling, though details vary. Many states also offer free NRT through the quitline.

Can I drink coffee or alcohol?

Coffee is fine, though it’s a strong trigger, so change something about the ritual for the first few weeks. Alcohol substantially raises relapse risk, especially in the first 3 months, and cutting it during the early quit is one of the highest-yield moves you can make. Some quitters return to moderate drinking after 6 to 12 months; for others alcohol stays a permanent risk.

If you have questions about quitting in the context of your specific cardiovascular history, or want help building a plan, our office can help. To get in touch, visit our practice website. For coordinated care, we work with the cardiovascular prevention team at San Diego Cardiovascular Associates.

References

1. US Surgeon General. The Health Consequences of Smoking, 50 Years of Progress. Atlanta, GA: US Department of Health and Human Services; 2014.

2. Wu AD, Lindson N, Hartmann-Boyce J, et al. “Smoking cessation for secondary prevention of cardiovascular disease.” Cochrane Database of Systematic Reviews. 2022.

3. Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovic D. “Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies.” BMJ. 2018;360:j5855.

4. Ding N, Sang Y, Chen J, et al. “Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases.” Journal of the American College of Cardiology. 2019.

5. Lindson N, Theodoulou A, Ordonez-Mena JM, et al. “Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.” Cochrane Database of Systematic Reviews. 2023.

6. Anthenelli RM, Benowitz NL, West R, et al. “Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES).” Lancet. 2016;387:2507-2520.

7. Eisenberg MJ, Windle SB, Roy N, et al. “Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome (EVITA).” Circulation. 2016;133:21-30.

8. Barua RS, Rigotti NA, Benowitz NL, et al. “2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment.” Journal of the American College of Cardiology. 2018.

9. Virani SS, Newby LK, Arnold SV, et al. “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease.” Journal of the American College of Cardiology. 2023.

10. Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. “Treatment of tobacco smoking: a review.” JAMA. 2022.

11. Lindson N, Livingstone-Banks J, Butler AR, et al. “Electronic cigarettes for smoking cessation.” Cochrane Database of Systematic Reviews. 2025.

12. Hu Y, Zong G, Liu G, et al. “Smoking cessation, weight change, type 2 diabetes, and mortality.” New England Journal of Medicine. 2018;379:623-632.

13. Jha P, Ramasundarahettige C, Landsman V, et al. “21st-century hazards of smoking and benefits of cessation in the United States.” New England Journal of Medicine. 2013;368:341-350.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.